PE20170291A1 - Vacunas contra virus de influenza y usos de las mismas - Google Patents

Vacunas contra virus de influenza y usos de las mismas

Info

Publication number
PE20170291A1
PE20170291A1 PE2017000043A PE2017000043A PE20170291A1 PE 20170291 A1 PE20170291 A1 PE 20170291A1 PE 2017000043 A PE2017000043 A PE 2017000043A PE 2017000043 A PE2017000043 A PE 2017000043A PE 20170291 A1 PE20170291 A1 PE 20170291A1
Authority
PE
Peru
Prior art keywords
influenza
domain
polypeptides
hemagglutinin
influenza viruses
Prior art date
Application number
PE2017000043A
Other languages
English (en)
Inventor
Antonietta Impagliazzo
Jan Wilem Meijberg
Katarina Radosevic
Michelle Wagner
Zhaoqing Ding
Original Assignee
Janssen Vaccines And Prevention B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063616&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines And Prevention B V filed Critical Janssen Vaccines And Prevention B V
Publication of PE20170291A1 publication Critical patent/PE20170291A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a polipeptidos de dominio de tallo de hemaglutinina de influenza multimericos que comprenden al menos un primer y un segundo monomeros de dicho dominio, donde cada monomero comprende: a) un dominio de hemaglutinina de influenza HA1 que comprende un segmento de tallo N-terminal de HA1 unido covalentemente a un segmento de tallo C-terminal de HA1; b) un dominio de hemaglutinina de influenza HA2 unido al segmento C-terminal de HA1; c) los polipeptidos no comprenden sitios de escision de proteasa en la union entre los dominios de HA1 y HA2; y d) los monomeros estan unidos mediante un puente disulfuro. Dichos polipeptidos son utiles en la deteccion, tratamiento o prevencion de la influenza
PE2017000043A 2014-07-10 2015-07-09 Vacunas contra virus de influenza y usos de las mismas PE20170291A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14176459 2014-07-10
US201462062754P 2014-10-10 2014-10-10
EP14195143 2014-11-27
EP15155761 2015-02-19

Publications (1)

Publication Number Publication Date
PE20170291A1 true PE20170291A1 (es) 2017-03-26

Family

ID=55063616

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000043A PE20170291A1 (es) 2014-07-10 2015-07-09 Vacunas contra virus de influenza y usos de las mismas

Country Status (17)

Country Link
US (1) US10117925B2 (es)
EP (1) EP3166963B1 (es)
JP (1) JP7094103B2 (es)
KR (1) KR102463632B1 (es)
CN (1) CN107074912B (es)
AU (1) AU2015286723B2 (es)
BR (1) BR112016030577A8 (es)
CA (1) CA2953451C (es)
CL (1) CL2017000064A1 (es)
EA (1) EA035375B1 (es)
MX (1) MX2017000395A (es)
MY (1) MY182440A (es)
PE (1) PE20170291A1 (es)
PH (1) PH12016502468A1 (es)
SG (1) SG11201610456UA (es)
WO (1) WO2016005482A1 (es)
ZA (1) ZA201700165B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
MX357009B (es) 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105452270B (zh) 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
SG11201610443WA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN118146389A (zh) 2016-09-02 2024-06-07 美国卫生与公众服务部 稳定化的第2组流感血凝素茎区三聚体及其用途
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN107765001B (zh) * 2017-10-24 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 禽流感病毒感染或禽流感疫苗免疫分型试剂盒
SG11202006399VA (en) 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
WO2019191257A1 (en) * 2018-03-28 2019-10-03 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising hemagglutinin
CN109239355B (zh) * 2018-09-05 2020-08-25 中牧实业股份有限公司 禽流感病毒h9亚型抗体酶联免疫检测试剂盒
US20210353738A1 (en) * 2018-09-21 2021-11-18 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes
CN114430742A (zh) * 2019-09-05 2022-05-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
CN116528893A (zh) * 2020-09-07 2023-08-01 英特维特国际股份有限公司 用于ha抗体阳性靶标的ha茎疫苗
TW202317600A (zh) * 2021-06-23 2023-05-01 潤惠生技股份有限公司 預防多種病毒感染的多價疫苗
WO2023154821A2 (en) * 2022-02-11 2023-08-17 University Of Washington Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2413962A1 (en) * 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
US8470327B2 (en) 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
KR20130075732A (ko) * 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
WO2012054745A1 (en) * 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
EA027054B1 (ru) 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
MX357009B (es) * 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
CN105452270B (zh) 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
SG11201610443WA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
AU2015286723B2 (en) 2019-11-21
CA2953451C (en) 2023-09-19
US10117925B2 (en) 2018-11-06
US20170189519A1 (en) 2017-07-06
MY182440A (en) 2021-01-25
EA035375B1 (ru) 2020-06-03
EA201692467A1 (ru) 2017-05-31
ZA201700165B (en) 2019-06-26
JP2017521073A (ja) 2017-08-03
CN107074912B (zh) 2021-10-29
EP3166963B1 (en) 2020-04-22
EP3166963A1 (en) 2017-05-17
CN107074912A (zh) 2017-08-18
WO2016005482A1 (en) 2016-01-14
PH12016502468B1 (en) 2017-04-10
KR102463632B1 (ko) 2022-11-03
SG11201610456UA (en) 2017-01-27
CA2953451A1 (en) 2016-01-14
BR112016030577A2 (pt) 2017-10-31
CL2017000064A1 (es) 2017-11-10
MX2017000395A (es) 2018-02-08
PH12016502468A1 (en) 2017-04-10
AU2015286723A1 (en) 2017-01-12
KR20170027846A (ko) 2017-03-10
JP7094103B2 (ja) 2022-07-01
BR112016030577A8 (pt) 2021-07-20

Similar Documents

Publication Publication Date Title
PE20170291A1 (es) Vacunas contra virus de influenza y usos de las mismas
PE20170290A1 (es) Vacunas contra virus de influenza y usos de las mismas
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
CO2017009061A2 (es) Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
EA201791735A1 (ru) Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
PH12014501118B1 (en) Influenza virus vaccines and uses thereof
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EA201592306A1 (ru) Вакцины против вируса гриппа и их применения
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
PE20210651A1 (es) Vacunas contra virus de la gripe y usos de las mismas
BR122020016505A8 (pt) Método para uso em levantamento de uma região de subsuperfície abaixo de um corpo de água pela detecção de ondas de compressão
BR112017005402B8 (pt) Sistemas de fusão e método de montagem
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
EA201600093A1 (ru) Дигидроксифенильные нейромедиаторные соединения, композиции и способы
MX363464B (es) Vacunas contra influenza h5.
BR112017004253A2 (pt) agentes antivirais e suas utilizações
BR112017024786A2 (pt) virus oncolíticos recombinantes e usos dos mesmos
EA201892385A1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.